BridgeBio Pharma, Inc. (BBIO)
74.27
+3.54
(+5.00%)
USD |
NASDAQ |
Oct 30, 12:25
BridgeBio Pharma Cash from Operations (Quarterly) : -71.10M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -71.10M |
| March 31, 2026 | -197.28M |
| December 31, 2025 | -56.42M |
| September 30, 2025 | -109.57M |
| June 30, 2025 | -80.68M |
| March 31, 2025 | -199.24M |
| December 31, 2024 | -195.33M |
| September 30, 2024 | -180.57M |
| June 30, 2024 | 74.70M |
| March 31, 2024 | -219.54M |
| December 31, 2023 | -124.82M |
| September 30, 2023 | -145.23M |
| June 30, 2023 | -113.35M |
| March 31, 2023 | -144.32M |
| December 31, 2022 | -92.12M |
| September 30, 2022 | -135.16M |
| June 30, 2022 | -30.45M |
| Date | Value |
|---|---|
| March 31, 2022 | -161.76M |
| December 31, 2021 | -133.90M |
| September 30, 2021 | -121.56M |
| June 30, 2021 | -91.71M |
| March 31, 2021 | -150.76M |
| December 31, 2020 | -96.26M |
| September 30, 2020 | -131.68M |
| June 30, 2020 | -87.85M |
| March 31, 2020 | -83.92M |
| December 31, 2019 | -76.20M |
| September 30, 2019 | -47.50M |
| June 30, 2019 | -69.81M |
| March 31, 2019 | -60.08M |
| December 31, 2018 | -46.41M |
| September 30, 2018 | -38.32M |
| June 30, 2018 | -33.96M |
| March 31, 2018 | -17.95M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -- |
| Pfizer Inc. | 835.00M |
| Ionis Pharmaceuticals, Inc. | 565.53M |
| Cytokinetics, Inc. | -159.84M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 17.89M |
| Cash from Financing (Quarterly) | -148.77M |
| Free Cash Flow | -437.79M |
| Free Cash Flow Per Share (Quarterly) | -0.3654 |
| Free Cash Flow to Equity (Quarterly) | -89.09M |
| Free Cash Flow to Firm (Quarterly) | -16.92M |
| Free Cash Flow Yield | -3.04% |